AYTU - AYTU BIOPHARMA, INC

QQQ $ 633.77 $ 0.00 (0 %)

DIA $ 475.02 $ 0.00 (0 %)

SPY $ 684.57 $ 0.00 (0 %)

TLT $ 90.29 $ 0.00 (0 %)

GLD $ 369.48 $ 0.00 (0 %)

Previous Close

$ 2.21

Open

$ 2.18

Bid

$ 1.00 x 2

Ask

$ 2.42 x 150

Day's Range

-- - --

52 Week Range

$ 0.95 - $ 2.82

Volume

89,361

Average Volume

Market Cap

21.91M

Beta (5Y Monthly)

$ 1.12

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	09-23-2025	06-30-2025	10-K
2	05-14-2025	03-31-2025	10-Q
3	02-12-2025	12-31-2024	10-Q
4	11-13-2024	09-30-2024	10-Q
5	09-26-2024	06-30-2024	10-K
6	05-15-2024	03-31-2024	10-Q
7	02-14-2024	12-31-2023	10-Q
8	11-14-2023	09-30-2023	10-Q
9	10-12-2023	06-30-2023	10-K
10	05-11-2023	03-31-2023	10-Q
11	02-21-2023	12-31-2022	10-Q
12	11-14-2022	09-30-2022	10-Q
13	09-27-2022	06-30-2022	10-K
14	05-16-2022	03-31-2022	10-Q
15	02-14-2022	12-31-2021	10-Q
16	11-15-2021	09-30-2021	10-Q
17	09-28-2021	06-30-2021	10-K
18	05-17-2021	03-31-2021	10-Q
19	02-11-2021	12-31-2020	10-Q
20	11-12-2020	09-30-2020	10-Q
21	10-06-2020	06-30-2020	10-K
22	05-15-2020	03-31-2020	10-Q
23	02-14-2020	12-31-2019	10-Q
24	11-14-2019	09-30-2019	10-Q
25	09-26-2019	06-30-2019	10-K
26	05-14-2019	03-31-2019	10-Q
27	02-07-2019	12-31-2018	10-Q
28	11-07-2018	09-30-2018	10-Q
29	09-06-2018	06-30-2018	10-K
30	05-14-2018	03-31-2018	10-Q
31	02-08-2018	12-31-2017	10-Q
32	11-09-2017	09-30-2017	10-Q
33	08-31-2017	06-30-2017	10-K
34	05-11-2017	03-31-2017	10-Q
35	02-09-2017	12-31-2016	10-Q
36	11-07-2016	09-30-2016	10-Q
37	09-01-2016	06-30-2016	10-K
38	05-11-2016	03-31-2016	10-Q
39	02-11-2016	12-31-2015	10-Q
40	11-06-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Aytu BioPharma Secures Patent Extension Fo...
10/28/2025 13:03:23

Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing inn...

Maxim Group Maintains Buy on Aytu BioPharm...
09/25/2025 14:39:03

Maxim Group analyst Naz Rahman maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and lowers the price target from $9 to $7.

Ascendiant Capital Maintains Buy on Aytu B...
09/25/2025 12:04:08

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $1...

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 17:06:12

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 21:07:00

Aytu BioPharma Q4 EPS $(2.92) Misses $(0.0...
09/23/2025 20:06:06

Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(2.92) per share which missed the analyst consensus estimate of $(0....

Earnings Scheduled For September 23, 2025
09/23/2025 08:32:08

Earnings Outlook For Aytu BioPharma
09/22/2025 14:02:13

FDA Issues Warning To Aytu Biopharma Over ...
09/16/2025 16:24:25

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aytu-biopharma-716599-09092025

12 Health Care Stocks Moving In Monday's A...
09/15/2025 21:06:07

Aytu BioPharma Transfers Rights To AR101 B...
08/07/2025 21:51:01

As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the "Company...

Lake Street Initiates Coverage On Aytu Bio...
07/01/2025 14:47:29

Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price T...

this-starbucks-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday

This Starbucks Analyst Begins Coverage On ...
06/30/2025 17:04:18

Ascendiant Capital Initiates Coverage On A...
06/30/2025 10:34:16

Ascendiant Capital analyst Edward Woo initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Pri...

Aytu BioPharma Expands And Extends Lending...
06/23/2025 12:14:16

Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 millio...

Aytu BioPharma Closes Upsized Public Offer...
06/09/2025 20:33:16

Gross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, includ...

Aytu BioPharma Prices Public Offering Of 1...
06/06/2025 20:11:08

On June 5, 2025, Aytu BioPharma, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agr...

Aytu BioPharma Prices Upsized Public Offer...
06/06/2025 12:12:55

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing....

Aytu BioPharma Enters Exclusive Agreement ...
06/06/2025 12:07:21

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-...